Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value.
Anti-chromatin (nucleosome) autoantibodies were one of the first autoantibodies ever detected since they make up the majority of antibodies causing LE Cell formation. The prevalence of anti-chromatin antibodies in systemic lupus erythematosus (SLE) varies from 50% to 100%, being similar to that of the classical positive LE cell. The presence of these antibodies can be used, in conjunction with clinical findings and other laboratory tests, to help in the diagnosis of SLE and drug-induced lupus. Anti-chromatin antibodies have also been found in a lesser percentage of other autoimmune disorders such as primary Sjögren's syndrome and primary antiphospholipid syndrome. The presence of anti-chromatin antibodies has also been linked to glomerulonephritis and disease activity in SLE patients. Recent studies demonstrated the induction of anti-chromatin (anti-nucleosome) antibodies after an anti-tumour necrosis factor (TNF)-alpha agent treatment.
Gómez-Puerta
José A
JA
Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
Burlingame
Rufus W
RW
Cervera
Ricard
R
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis* / Q000096:biosynthesis / Q000502:physiology; D002843:Chromatin / Q000276:immunology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000276:immunology; D009707:Nucleosomes / Q000276:immunology*
D000974:Antibodies, Antinuclear; D002843:Chromatin; D009707:Nucleosomes